

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please add new claims 11-13, as follows:

1. (Original) A prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors.
2. (Original) A prophylactic antimigraine agent as claimed in Claim 1, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and b) a 5-HT₇ receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT₇ receptor.
3. (Original) A prophylactic antimigraine agent as claimed in Claim 1, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a dual antagonistic compound for the 5-HT_{2B} and 5-HT₇ receptors having a selective binding affinity to both of the 5-HT_{2B} and 5-HT₇ receptors.
4. (Original) A combined prophylactic preparation for migraine which comprises a) a first pharmaceutical preparation comprising as an active ingredient a 5-HT_{2B} receptor antagonistic compound having a selective binding affinity to the 5-HT_{2B} receptor, and b) a second pharmaceutical preparation comprising as an active ingredient a 5-HT₇ receptor antagonistic compound having a selective binding affinity to the 5-HT₇ receptor, and wherein the first and second preparations are administered simultaneously or separately.

5. (Previously Presented) A prophylactic antimigraine agent as claimed in Claim 1, wherein the binding affinity for the 5-HT_{2B} and 5-HT₇ receptors is respectively one hundredth or more to the α₁, M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

6. (Original) Use of the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors for the manufacture of a prophylactic antimigraine agent.

7. (Original) Use of "a 5-HT_{2B} receptor antagonistic compound having a selective binding affinity to the 5-HT_{2B} receptor" for the manufacture of a prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors.

8. (Original) Use of "a 5-HT₇ receptor antagonistic compound having a selective binding affinity to the 5-HT₇ receptor" for the manufacture of a prophylactic antimigraine agent comprising as an active ingredient a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors.

9. (Original) A method for prophylaxis of migraine which comprises administering a therapeutically effective amount of a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors to a patient.

10. (Original) A method for prophylaxis of migraine which comprises administering a combination comprising a pharmaceutical preparation containing as an

active ingredient a 5-HT_{2B} selective receptor antagonistic compound and a pharmaceutical preparation containing as an active ingredient a 5-HT₇ receptor selective antagonistic compound, simultaneously or separately to a patient.

11. (New) The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises:

- a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and
- b) a 5-HT₇ receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT₇ receptor.

12. (New) The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a dual antagonistic compound for the 5-HT_{2B} and 5-HT₇ receptors having a selective binding affinity to both of the 5-HT_{2B} and 5-HT₇ receptors.

13. (New) The method of claim 9, wherein the binding affinity for the 5-HT_{2B} and 5-HT₇ receptors is respectively one-hundredth or more to the α₁, M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.